drugset / Trial / NCT06075277
A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food
RandomizedCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to investigate the relative bioavailability of a single dose of BI 1810631 intended commercial formulation (iCF) under fed (Test treatment, T) and fasted (Reference treatment, R) conditions.
Timeline
- Start
- 2023-10-19
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zongertinib | Small molecule | 240 mg | Oral |
Indications
No indication recorded.